Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 11 - 20 of about 75   

Articles published

ARNA 4.16 -0.01 (-0.24%)
price chart
Belviq Sales Flat - Model Your Expectations (ARNA)
Sales of Arena Pharmaceuticals' (NASDAQ:ARNA) Belviq were essentially flat this week vs. last week, according to industry tracker IMS Health (NYSE:IMS).
Related articles »  
Volatile Stocks to Watch: Arena Pharmaceuticals, Inc. (ARNA), Citrix Systems ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced that data from the Phase 3 clinical trial program for BELVIQ� (lorcaserin HCl) CIV has presented at the American College of Clinical Pharmacy (ACCP) Annual Meeting taking place October 12-15, ...
Related articles »  
Investor Updates : Auxilium Pharma , Avanir Pharma , Arena Pharma , Novavax ...
Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) : On October 2, Meeting held at Boston hosted by Jefferies. Auxilium (AUXL) downgraded to Sector Perform from Outperform at RBC Capital.
Trend Analysis Report � Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), FED ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors.
Volatile Stocks in List: Gilead Sciences, Inc.(NASDAQ:GILD), Arena ...
Arena Pharmaceuticals, Inc.(NASDAQ:ARNA) with OODCLIFF LAKE, N.J. and SAN DIEGO declared on last Friday session that a group analysis of the BLOOM and BLOSSOM pivotal, Phase 3 clinical trials of BELVIQ� (lorcaserin HCl) was printed in the ...
Related articles »  
Don't Miss : Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Caterpillar Inc ...
Contrave is a combination of two Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Vivus Inc. drugs that were approved by the FDA in 2012, ABC News reports, after having spent 13 years without approving any weight-loss medication.
News Recap � CYS Investments (CYS), Arena Pharmaceuticals, Inc. (ARNA ...
CYS Investments Inc (NYSE:CYS) declared financial results for the quarter ended June 30, 2014. June 30, 2014 book value per common share of $10.31 after declaring a $0.32 dividend per common share on June 9, 2014, compared to our book value of ...
Related articles »  
Traders Are Watching: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Johnson ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced today that the company is scheduled to present a corporate overview and update at the NewsMakers in the Biotech Industry conference on Friday, September 26, 2014, at 11:30 a.m.
Stocks Trending Alert-CEL-SCI (NYSEMKT:CVM), Arena Pharmaceuticals ...
Miami, Florida - Oct 22, 2014 - (Tech Sonian) �CEL-SCI Corporation (NYSEMKT:CVM) has agreed to sell common stock and warrants in a registered direct offering to European investors at a combined price of $0.76 for aggregate gross proceeds of a little ...
Belviq Sales Rise Almost 5% Week Over Week
Sales of Belviq, the anti-obesity drug from Arena Pharmaceuticals (NASDAQ:ARNA) were up this week and now pacing slightly ahead of the "guidance" pace I outlined many months ago.
Eisai and Arena Pharmaceuticals Announce Publication of Pooled Phase 3 ...  CNNMoney
Related articles »